Lpl Financial LLC Recursion Pharmaceuticals, Inc. Transaction History

Lpl Financial LLC

$218 Billion
Q3 2024

A detailed history of Lpl Financial LLC transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Lpl Financial LLC holds 360,438 shares of RXRX stock, worth $2.23 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

360,438

Previous 319,469 12.82%

Holding current value

$2.23 Million

Previous $2.4 Million 0.88%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 08, 2024	BUY	$5.92 - $8.6 $242,536 - $352,333	40,969 Added 12.82%	360,438 $2.38 Million
Q2 2024 Aug 07, 2024	BUY	$7.35 - $10.05 $820,605 - $1.12 Million	111,647 Added 53.72%	319,469 $2.4 Million
Q1 2024 May 10, 2024	BUY	$9.13 - $15.52 $623,761 - $1.06 Million	68,320 Added 48.97%	207,822 $2.07 Million
Q4 2023 Feb 14, 2024	BUY	$5.09 - $10.79 $361,858 - $767,082	71,092 Added 103.92%	139,502 $1.38 Million
Q3 2023 Nov 13, 2023	BUY	$6.59 - $15.86 $113,380 - $272,871	17,205 Added 33.6%	68,410 $523,000
Q2 2023 Jul 31, 2023	BUY	$4.56 - $9.94 $69,061 - $150,541	15,145 Added 42.0%	51,205 $382,000
Q1 2023 May 10, 2023	SELL	$6.42 - $9.64 $62,916 - $94,472	-9,800 Reduced 21.37%	36,060 $240,000
Q4 2022 Feb 07, 2023	BUY	$7.16 - $12.7 $29,334 - $52,031	4,097 Added 9.81%	45,860 $353,000
Q3 2022 Nov 14, 2022	SELL	$7.83 - $13.6 $3,711 - $6,446	-474 Reduced 1.12%	41,763 $444,000
Q2 2022 Aug 12, 2022	BUY	$5.04 - $9.26 $212,874 - $391,114	42,237 New	42,237 $344,000

Others Institutions Holding RXRX

# of Institutions

286

Shares Held

242M

Call Options Held

1.35M

Put Options Held

2.32M

View Full List

About RECURSION PHARMACEUTICALS, INC.

Ticker RXRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 180,480,000
Market Cap $1.12B
Description
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...

More about RXRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Lpl Financial LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lpl Financial LLC with notifications on news.

Account

Lpl Financial LLC Recursion Pharmaceuticals, Inc. Transaction History